ArticleScientific reports2025
Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is an exceptionally rare form of primary liver malignancy and currently lacks prognostic prediction models. This study aims to develop a nomogram designed to predict cancer-specific survival (CSS) in patients diagnosed with cHCC-CCA. A total of 420 patients diagnosed with cHCC-CCA between 2004 and 2019 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly assigned to training and validation cohorts in a 7:3 ratio. Cox proportional hazards regression analysis was employed to identify prognostic factors for the construction of the nomogram. The performance and clinical utility of the nomogram were evaluated using the concordance index (C-index), area under the curve (AUC) values, calibration curves, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Ultimately, Multivariate Cox regression analysis identified 6 variables for the establishment of a nomogram for cHCC-CCA. The C-index, AUC value and calibration curve of the nomogram show that the model has satisfactory accuracy. Additionally, DCA, NRI values (training set: 0.392 for 1-year, 0.425 for 3-year and 0.414 for 5-year CSS prediction), and IDI (training set: 0.165 for 1-year, 0.151 for 3-year and 0.151 for 5-year CSS prediction) indicate that the performance of the established nomogram is significantly better than that based solely on the AJCC standard tumor staging (P < 0.05). Furthermore, a risk classification system with enhanced capability to identify patients at varying risk levels was established. Therefore, we developed a nomogram that can help clinicians assess the prognosis of patients with cHCC-CCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.